X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to co-develop Helicon-enabled 212Pb alpha radioligand therapies by leveraging FogPharma’s field-leading Helicon platform and ARTBIO’s AlphaDirect™ platform, for cancer.
Lead Product(s): 212Pb Alpha Radioligand Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: FogPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 14, 2024
Details:
Under the terms of the agreement, Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001 (212Pb-NG001), using ARTBIO’s proprietary AlphaDirectTM 212Pb isolation technology.
Lead Product(s): 212Pb-NG001
Therapeutic Area: Oncology Product Name: AB001
Highest Development Status: Phase IProduct Type: Peptide
Recipient: Nucleus RadioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 07, 2024
Details:
Under the agreement, PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 (212Pb-NG001), using ARTBIO's proprietary AlphaDirect™ 212Pb isolation technology.
Lead Product(s): 212Pb-NG001
Therapeutic Area: Oncology Product Name: AB001
Highest Development Status: Phase IProduct Type: Peptide
Recipient: PharmaLogic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 12, 2024
Details:
The partnership aims to produce a novel prostate cancer therapy known as AB001 (212Pb-NG001), a promising therapy for prostate cancer, by utilizing SpectronRx's expertise and state-of-the-art facilities.
Lead Product(s): 212Pb-NG001
Therapeutic Area: Oncology Product Name: AB001
Highest Development Status: Phase IProduct Type: Peptide
Recipient: SpectronRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 09, 2024
Details:
The proceeds will be used to help solidify ARTBIO's proprietary Pb212 isolation technology AlphaDirect™ and its distributed manufacturing network, advance its lead program AB001 (212Pb-NG001) in the clinic for treatment of prostate cancer, and further the company's pipeline.
Lead Product(s): 212Pb-NG001
Therapeutic Area: Oncology Product Name: AB001
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Third Rock Ventures
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 07, 2023
Details:
The financing enables ARTBIO's ongoing clinical development of its lead program AB001 (212Pb-NG001) for the treatment of prostate cancer and will advance its AlphaDirect™ Pb212 isolation technology.
Lead Product(s): 212Pb-NG001
Therapeutic Area: Oncology Product Name: AB001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: F-Prime Capital
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
